Australia biotech gets U.S. approval for first spinal stem cell trial

12/20/2006 | Age (Melbourne, Australia), The

The U.S. FDA has cleared an Australia firm to try the world's first use of stem cells to treat degenerative spinal disease in humans. Mesoblast, a Melbourne-based biotech, said the FDA allowed it to go directly to the Phase II stage after animal trials proved promising for the adult stem cell treatment that could replace the need for bone grafts.

View Full Article in:

Age (Melbourne, Australia), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD